BCTX BRIACELL THERAPEUTICS CORP Operational Disruptions 8-K Filing 2024 - Press Release BriaCell Therapeutics Corp. announced significantly higher progression free survival for its top responder patient in the Phase 2 study of the Bria-IMT regimen in combination with an immune checkpoint inhibitor in metastatic breast cancer.Get access to all SEC 8-K filings of the BRIACELL THERAPEUTICS CORP